Previously, K6PC-5, a synthetic derivative of ceramide, was demonstrated to activate sphingosine kinase (SK)-l in keratinocytes. In this study its potential biological effect in mouse myoblasts was examined. The obtained results show that K6PC-5 promotes myogenic differentiation by enhancing myogenic marker expression, differentiation index and fusion index. Interestingly, its biological action was prevented by pharmacological inhibition of SK or SlP 2 receptor, in full agreement with their recognized role in myoblast differentiation. This is the first evidence that pharmacological activation of SK accelerates myogenesis and suggests that this new therapeutic strategy could be possibly employed in skeletal muscle disorders where muscle regeneration is deficient.
The bioactive lipid sphingosine l-phosphate (SIP) and its endogenous metabolism playa pivotal role in the control of biological processes such as cell proliferation, motility and survival (1) (2) (3) . We previously highlighted a novel role for SIP in differentiation of cultured myoblasts, demonstrating that via ligation to its receptor SIP2' it enhances the expression of skeletal muscle marker proteins (4) . Moreover, we showed that the expression of sphingosine kinase-l (SKI), responsible for SIP formation within the cells, was enhanced in confluent myoblasts and at early stage of differentiation into myotubes. Interestingly, the blockade of SKI impaired cell growth arrest and differentiation, whereas its overexpression increased the pace of myogenesis in vitro (5) . In agreement, stimulation of SIP formation induced by tumor necrosis factor (TNF)-a at low concentration was identified as a molecular mechanism whereby the cytokine exerts its pro-myogenic effect in cultured myoblasts (6) . Importantly, SIP was identified to act as a trophic factor for adult skeletal muscle (7) and was also found implicated in skeletal muscle regeneration in vivo (8) , reinforcing the notion that SKlISIP axis is critical in many different biological processes that characterize skeletal muscle phenotype.
Recently, synthesized novel ceramide derivatives have been shown to mimic the pro-differentiating effect of SIP in epidermal keratinocytes (9) . Interestingly, one of these compounds, which contains a ketone group, two hydroxy groups, two short alkyl groups, and an amide linkage with a chemical name of N-( I,3-dihydroxyisopropyl)-2hexyl-3-oxo-decanamide (K6PC-5) was further demonstrated to act as direct activator of SK 1. Stimulation with K6PC-5 resulted in terminal differentiation of keratinocytes triggering specific signaling pathways such as intracellular calcium increase, suggesting that it could represent a novel approach for the treatment of skin disorders (10) . Additional in vivo studies also confirmed the prodifferentiating effects of K6PC-5 in a murine model, mainly through the simulation of SIP signaling ( 11 ).
In view of the important role played by SK I/S 1P axis in skeletal muscle cell biology and its positive effect on cell differentiation (4; 12) , in this study the effect of K6PC-5 in mouse myoblasts was investigated.
The results obtained demonstrate that this ceramide derivative is capable of enhancing myogenic differentiation, supporting the view that its employment could be of help also in a number of pathological conditions in which skeletal muscle repair is impaired.
MATERIALS AND METHODS

Materials
Biochemicals, cell culture reagents, Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), protease inhibitor cocktail, monoclonal antiskeletal fast myosin heavy chain (MyHC) (clone MY-32) and bovine serum albumin (BSA) were from Sigma (St. Louis, MO, USA). Mouse skeletal muscle C2CI2 cells were obtained from the American Type Culture Collection, (Manassas, VA, USA). SKI-2 (2-(P-hydroxyanilino)-4-(P II chlorophenyl)thiazole), D-erythro-S IP and propidium iodide (PI) were from Calbiochem (San Diego, CA, USA). Monoclonal anti-caveolin-3 was from Transduction Laboratories (Lexington, KY, USA). The specific antagonist ofS IP 2 , JTE 013 (13) was from Tocris Cookson Limited (Bristol, UK). K6PC-5 was synthesized as previously described (9) . Antibodies against myogenin (F5D),~-actin (C-II), pan-Akt (H-136), phospho-pan-Akt (Ser 473), anti-mouse, anti-rabbit, and anti-goat immunoglobulin G I conjugated to horseradish peroxidase and Blotto (non-fat dried milk) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Phospho-ERKI/2 and pan-ERKI/2, phospho-p38 and pan-p38 antibodies were from Cell Signaling Technology, Inc. (Beverly, MA, USA). Enhanced chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech (Uppsala, Sweden). CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay was from Promega (Madison, WI, USA). Fluorescein-conjugated horse anti-mouse secondary antibody was obtained from Vector (Burlingame, CA, USA).
Cell culture
C2CI2 mouse myoblasts were grown in DMEM supplemented with 10% FCS. For proliferation experiments, cells were seeded in 96-well plates and used when -40% confluent. For differentiation experiments, cells were seeded in 60-mm-diameter dishes and, when confluent, were shifted to DMEM without serum containing I mg/ml BSA. When appropriate, the specific inhibitor of SK (SKI-2, 10~M) (14) or the specific SIP2 antagonist JTE 013 (I~M) were administered to the cells 30 min before agonist addition.
Cell proliferation
Cell proliferation was measured in serum-starved cells challenged with different concentrations of K6PC5 by MTS-dye reduction assay, according to Promega CellTiter 96® Non-Radioactive Cell Proliferation Assay's instructions, as previously described (4) .
Western blot analysis
Total cell extracts were prepared and subjected to SDS-PAGE and Western blot analysis, as previously described (4) .
Cell immunofluorescence
Cells were seeded on microscope slides, pre-coated with 2% gelatine, and then treated or not with K6PC-5 or SIP. After 72 h cells were fixed in 2% paraformaldehyde in PBS for 20 min and permeabilized in 0.1% Triton X-IOO-PBS for 30 min. Cells were then blocked in 3% BSA for I h and incubated with anti-MyHC antibody for 2 h and fluorescein-conjugated anti-mouse secondary antibody for 1 h. To stain nuclei, the specimen was incubated with 50 ug/ml propidium iodide in PBS for 15 min. Images were obtained using a Leica SP5 laser scanning confocal microscope with 40X objective. To quantify the differentiation and fusion of C2CI2 cells after treatments, we calculated the differentiation index as the percentage of MyHC-positive cells above total nuclei and the fusion index as the average number of nuclei in MyHC-positive cells with at least three nuclei above total number of nuclei, respectively.
RESULTS
To establish the biological effect exerted by K6PC-5 in mouse myoblasts, it was initially examined whether this ceramide analogue could influence cell proliferation. For this purpose, C2C 12 cells, approximately 40% confluent, were treated with different concentrations of K6PC-5 and subjected to MTS-dye reduction assay to evaluate cell number. The data presented in Fig. lA show that K6PC-5 in the concentration range 5-25 uM did not affect myoblast growth. Similar results were obtained when cell proliferation was evaluated by measuring radioactive thymidine incorporation into DNA (data not shown). The potential action ofK6PC-5 was then studied on myoblast differentiation into myotube. To this end, cellular content of skeletal muscle marker proteins such as MyHC, myogenin and caveolin-3, normally absent in immature myoblasts but strongly expressed in differentiated cells, was determined by Western blot analysis. As illustrated in Fig. 1B , K6PC-5 at all the tested concentration (5-25 flM) was capable of enhancing the expression of the three myogenic markers after 48 h of incubation in sub-confluent, serum-starved myoblasts, 10 flM K6PC-5 being the most efficacious concentration, showing approximately three-fold increase of MyHC and caveolin-3 and five-fold increase of myogenin. Based on these results, all the subsequent experiments were performed employing 10 uM K6PC-5. Since myogenic differentiation is a timedependent process and the chosen protein markers have a different time-course of expression, the transcription factor myogenin being the most precocious and the structural protein caveolin-3 being the latest, we then examined the effect of K6PC-5 on myogenic differentiation at different time-points. Results presented in Fig. 1C show that, in agreement with the release of autocrine differentiation factors (15) (16) , the marker expression in unchallenged myoblasts was enhanced in a timedependent manner; moreover, myoblast treatment with 10 uM K6PC-5 increased the expression of the early marker myogenin at 24 and 48 h, that of the late marker caveolin-3 at 48 and 72 h and that of intermediate marker MyHC at all the examined time-points.
To provide further evidence that K6PC-5 exerts a myogenic action, we investigated whether it affects differentiation and fusion of myoblasts. Indeed, after 72 h treatment, differentiation index was augmented by 50% and fusion index increased up to two-fold compared with untreated cells (Fig. 2) . Interestingly, in the same figure it is shown that I~M SIP, known inducer of myogenic marker expression (4), as expected, exerted a stimulatory effect on differentiation index and fusion index which was superimposable to that elicited by K6PC-5.
With the aim of gaining insight into the mechanism by which K6PC-5 induces its biological effect, the phosphorylation status of key signaling protein kinases such as p38 MAPK, ERKl/2 and Akt was subsequently evaluated. Western analysis of the phosphorylated forms of these protein kinases indicates that the ceramide derivative was responsible for an early and transient activation of p38 MAPK and ERKl/2 which was not detectable after 30 min of incubation (Fig. 3) . In contrast, 10 M K6PC-5 did not influence the phosphorylation Fig. 3 . K6PC-5 activates p38 MAPK and ERKJ/ERK2 in C2C12 myobiasts. Serum-starved confluent myoblasts were incubated with (+) or without (-) 10 fJM K6PC-5 for the indicated times. Cell lysates were immunoblotted using specific antibodies. A blot representative of 3 independent experiments is presented. Band intensity corresponding to phosphorylatedprotein was normalized to its total content and reported as a percentage relative to control (time 0, no addition) set as 100.
extent ofAkt. Finally, to investigate whether the mechanism by which K6PC-5 induces its pro-myogenic effect involves the regulation of myoblast SIP metabolism, the effect of the ceramide derivative on the myogenic -marker expression was examined in myoblasts in which SK was inhibited by prior incubation with the specific inhibitor SKl-2 (10~M), or SIP 2 receptor was blocked by the selective antagonist JTEO13 (I~M). In both these experimental conditions the positive effect of K6PC-5 on the expression of myogenin, MyHC and caveolin-3 was abrogated ( Fig. 4) in favour of the hypothesis that it elicits the biological response via stimulation of SK, leading to increase of cellular SIP that, after being released outside the cell, triggers cell differentiation by SIP 2 engagement (Fig. 5) . 
DISCUSSION
Studies carried out in recent years have clearly demonstrated that the SKIS IP axis and the downstream signaling events playa critical role in skeletal muscle cell biology, suggesting that targeting this signaling pathway could represent a promising new approach for treating multiple skeletal muscle disorders characterized by an altered regeneration process (12) . In this study, we examined in mouse myoblasts the biological effect exerted by K6PC-5, a synthetic ceramide derivative known to activate SK I in keratinocytes (9, ) I), demonstrating that also in this cell type it acti vates SK, since its biological acti vity was fully aboli shed by cell treatment with SKI-2 , a selective inhibitor of SK. More importantly, here we provide evidence that the pharmacological action of this compound is capable of fully mimicking the positive effect exerted by exogenous SIP on myoblast differentiation, since it enhanced the expression of known myogenic markers such as myogen in, MyHC and caveolin-3. similarly to that prev iously shown in response to SIP treatment (4) and, equally to SIP, significantly augmented two key parameters such as differentiation index and fusion index. In further agreement with SIP action in rnyoblasts, K6PC-5 did not influence per se cell proliferation. Moreover, here a new clue is added to the mechanism by which K6PC-5 brings about its effect. Indeed, SIP2 receptor antagonism performed with the specific compound JTEO 13 prevented its biological action, thus demonstrating that SIP formed upon stimulation of SK by K6PC-5, subsequently to its release outside the cell, was able to trigger myoblast differentiation via interaction with SIP2' in complete analogy to what was observed upon delivery of SIP to mouse myoblasts (4) . Although this finding could appear simply confirmatory, this issue is not trivial since the intracellularly-formed SIP can elicit its biological response in a complex manner, acting either as intracellular mediator capable of directly modulating activity/functionality of key proteins such as histone deacetylases (17) or, subsequently to its export in the extracellular environment, as ligand of a family of five specific G-protein coupled receptors named SIP receptors (18) . It has been previously shown that intracellular SIP generated in myoblasts after serum depri vation or in response to low concentration ofTN Fa induced myoblast differentiation by ligation to S IP 2 (5, 6) , in full agreement with the mechanism by which exogenous SIP acts. At variance, intracellular SIP formed in myoblasts in response to PDGF, acts through a similar inside-out mechanism but engages exclusively SIPI' thus mediating inhibition of cell proliferation and not cell differentiation (19) . This different outcome appears to be attributable to the regulation by PDGF of a discrete pool of SKI that can favour the export of SIP outside cell membrane in close proximity of SIPI' which although highly expressed in these cells is unresponsive to the selective agonist SEW287I, probably due to its peculiar membrane topology (20) . Therefore, the pro-myogenic effect described here of K6PC-5 exerted via SIP2 transactivation indicates that the activation ofSK by the compound involves the same pool of enzyme that accounts for the physiological process of myoblast differentiation initiated by serum deprivation, that enables the engagement of SIP2' essential for this biological response.
In this study, the signaling pathways triggered by K6PC-5 were also investigated. Interestingly, p38 MAPK and ERKI/2 were found to be transiently activated by this compound. Indeed, p38 MAPK activation by SIP was reported crucial for its promyogenic effect, while ERKI/2 was described to be involved in the cell cycle arrest caused by the bioactive lipid (4), therefore the present findings are fully coherent with a signaling process initiated by K6PC-5-induced SIP formation. However, K6PC-5 treatment, differently from exogenous SIP (4), did not provoke Akt activation. Although this signaling pathway was found marginally implicated in the pro-myogenic effect of SIP, this discrepancy could be explained taking into account that Akt is only partially coupled to SIP z in these cells (4), whereas the signaling of SIP formed in response to K6PC-5 is very likely strictly Sl Pj-dependent, being the biological response fully abolished by blockade of SIP z · The present disclosure of an activator of SK I as inducer of myoblast differentiation supports the notion that the signaling axis of SKIS I P is crucial for the accomplishment of mature phenotype of skeletal muscle cells. Moreover, it represents the first evidence that its pharmacological modulation can be pursued to accelerate this biological process. These promising results obtained in isolated cells in vitro solicit further investigation of this issue in regenerating skeletal muscle in vivo. Indeed, SIP formation inside cells is an ubiquitous event and by virtue ofinteracting with different receptors, this lipid is endowed with multiple properties, also opposite in different cells (21, 22) . For this reason it will be important to examine the consequences on tissue repair of broad SK activation at the site of muscle lesion caused by pharmacological activators, since it could not only positively influence satellite cells, by promoting their differentiation, but also affect the functioning of various types of inflammatory cells that are known to actively participate in skeletal muscle healing.
